Key result
Fondaparinux matches enoxaparin efficacy in ACS with lower bleeding risk, but UFH remains preferred for primary PCI.
Why the study?
Fondaparinux is a new anticoagulant with evidence suggesting comparable or superior efficacy and safety to enoxaparin and unfractionated heparin in various thrombotic conditions, but its role in different cardiology settings requires clarification.
What is the efficacy and safety of fondaparinux compared to enoxaparin and unfractionated heparin across various clinical scenarios including VTE prevention/treatment and acute coronary syndromes?
What is the efficacy and safety of fondaparinux compared to enoxaparin and unfractionated heparin across various clinical scenarios including VTE prevention/treatment and acute coronary syndromes?
Fondaparinux is an effective anticoagulant with a favorable bleeding profile in acute coronary syndromes, though unfractionated heparin remains preferred during primary PCI for STEMI due to catheter thrombosis risks.
May support fondaparinux in VTE/ACS for bleeding reduction; leaves open optimal PCI strategies amid evolving regimens.
Fondaparinux is a synthetic pentasaccharide belonging to a new group of anticoagulants that inhibit thrombin formation by inhibiting Factor Xa, which is located at the crossing of both the intrinsic and extrinsic pathways. It has a favorable pharmacokinetic profile, and its effect is predictable and the drug does not need platelet monitoring. Current evidence suggest that fondaparinux is as effective as, if not more than, enoxaparin in the prevention of venous thromboembolism in the postoperative period. It has also been found to have similar effectiveness to enoxaparin and unfractionated heparin in the treatment of venous and pulmonary embolism, respectively. In the field of cardiology, studies have demonstrated that in the setting of acute coronary syndromes, treatment with fondaparinux is not inferior to enoxaparin in preventing major cardiac outcomes, but it is associated with lower risk of bleeding complications, irrespective of the use of percutaneous coronary intervention. During percutaneous coronary intervention, there is a slightly increased risk of catheter thrombosis, which is removed when used along with unfractionated heparin. However, in patients with ST-elevation myocardial infarction, the benefit has been shown in those either receiving thrombolysis or not undergoing any revascularization, but not in subjects undergoing primary percutaneous coronary intervention where unfractionated heparin is still preferred.
No takes yet. Share an insight, caveat, or question.
Nadar et al. (2009) conducted a review in Venous thromboembolism and acute coronary syndromes. Fondaparinux vs. Enoxaparin and unfractionated heparin was evaluated. Fondaparinux is effective for VTE management and noninferior to enoxaparin in acute coronary syndromes with lower bleeding risk, though unfractionated heparin is preferred in primary PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: